Summary: Coagulation and fibrinolysis activation have been investigated in fifty-eight women with recently detected gynaecological tumours. Twenty-six were benign and 32 malignant: of the last group nine patients had metastases. A control group consisted of 31 age-matched healthy women. Prothrombin fragment 1 + 2, thrombinantithrombin III and D-dimer were measured. The median values of all analytes were significantly higher in the malignant tumour group, but not in the benign tumour group, as compared to the control group. The group of patients with a gynaecological tumour and metastases differed from the non-metastasized tumour group in prothrombin fragment 1-1-2, thrombin-antithrombin III and D-dimer. In the non-metastasized malignant tumour group solely prothrombin fragment 1 + 2 was significantly higher than in the benign tumour group. Coagulation and fibrinolysis appeared to be activated in the patients with a metastasized gynaecological tumour, fibrinolysis predominating as can be derived from the elevated D-dimer/thrombin-antithrombin III and D-dimer/prothrombin fragment 1 + 2 ratios. The studied constituents do not enable a differentiation between the benign and malignant processes. However, as the differences of these values in both malignant tumour groups were significant, this might be used to trace the existence of metastases in gynaecological tumours. Investigation of these analytes in several specific types of gynaecological tumours might be clinically relevant.
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Materials and Methods

Patients
Plasma samples were collected from 58 patients with suspicion of a benign or malignant gynaecological tumour and subsequent diagnostic confirmation by histology. On admission to the hospital no patient showed clinical signs of bleeding or thrombosis. Twenty-six patients had a benign disease (tab. 1) and 32 patients a malignancy (tab. 2). In the latter group nine patients had metastases histologically proven mostly in lymph nodes or peritoneal tissue. The use of medication was excluded. A reference group consisted of 31 age-matched ostensibly healthy women.
Samples
Blood samples were drawn between 8.30 and 9.00 a. m. after fasting overnight for 10 h and a resting period of 20 min.
The various constituents were determined in citrated plasma. This was prepared by centrifugation of a mixture of nine volumes freshly drawn blood with one volume trisodium citrate (0.11 mol/1) during 30 min (1600 g) at 25 °C. The plasma was stored at -70 °C in plastic tubes and thawed at 37 °C for 5 min before batch analysis.
Methods
The prothrombin fragment 1 -I-2 test was determined with an ELISA test kit (Behring Corporation, Marburg, Germany). For the thrombin-antithrombin III determination an ELISA test kit was used (Behring, Marburg, Germany). The fibrin degradation products were measured by means of the D-dimer test of BoehringerMannheim (Mannheim, Germany). The D-dimer/thrombinantithrombin III and the D-dimer/prothrombin fragment 1 + 2 ratio were calculated on molar basis as arbitrary measures of the fibrinolysis/coagulation balance.
The Mann-Whitney U test and the x 2 -test, where appropriate, were used for statistical analysis.
Results
In table 1 the diagnoses of the patients with a benign disease are given. Ovarian cysts occur most in this group. ntithrombin III ratio and D-dimer/prothrombin fragment 1 + 2 ratio were significantly increased in the group with metastases. Table 5 gives the percentages of decreased and increased values of the various coagulation and fibrinolysis constituents in the three patient groups based on the laboratory reference ranges.
Between the benign and the non-metastatic tumour group significantly different proportions of increased values were found for prothrombin fragment 1 + 2 and for D-dimer. The percentages of increased values between the non-metastatic and metastatic tumour groups were significantly different for thrombin-antithrombin III and D-dimer. 
Discussion
The patients with a benign gynaecological tumour did not differ significantly in comparison with the control group with the exception of the D-dimer/thrombinantithrombin ratio. The malignant tumour group however, showed, compared to the control group, significant differences for all measured quantities. Subdivision of the malignant tumour, group in a group with and a group without metastases revealed that the devi-The results reflect a substantial activation of blood coagations in the total malignant tumour group were ulation (prothrombin fragment 1 + 2, thrombinmainly due to the patients with metastases. antithrombin III) with reactive fibrinolysis (D-dimer). This phenomenon has also been reported in a number of other cancer types (14) (15) (16) . The elevated thrombinantithrombin HI levels are consistent with an earlier study on this topic, in which thrombin-antithrombin III was considered a marker of malignant gynaecological disease (17) . In general, an explanation for the activation of blood coagulation in tumours is thought to be a direct interaction of the coagulation factors with tumour cells (18, 19) or an indirect production of cytokines (20) . The evidence for both of these etiologies are however based on immunohistological investigations. An alternative, well-documented explanation is the evidence for the production of "cancer procoagulants", which have been shown to be produced by a large number of cell lines tested (21) .
We calculated the D-dimer/thrombin-antithrombin III ratio and the D-dimer/prothrombin fragment 1 + 2 ratio as arbitrary measures for the balance of the fibrinolysis/ coagulation system. Both ratios were increased in favour of fibrinolysis, being the highest in patients with metastases. The D-dimer/prothrombin fragment 1 + 2 ratio showed a more pronounced increase than that of D-dimer/thrombin-antithrombin III, probably because prothrombin fragment 1 + 2 and thrombin-antithrombin III differ in production and elimination rates. Fibrinolysis seems to dominate over the coagulation system, therewith possibly preventing thrombotic events. Nevertheless, when the quantities of fibrinolysis and coagulation are enhanced the risk for such an event may be increased (1-3,22-24).
In conclusion, it is not possible to differentiate between a benign and a malignant process on the basis of the constituents studied. The haemostasis quantities seem, however, to give an indication of the existence of metastases in patients suspected of malignant gynaecological tumours, although we are aware that the studied patient groups are rather heterogeneous. Therefore a follow-up study is ongoing focussing on the more frequent gynaecological cancer types e.g. ovarian cancer and cervix cancer. Moreover, more research will be necessary to evaluate the clinical impact of the elevated level of the fibrinolysis/coagulation balance in patients with the mentioned gynaecological cancer types.
